Apoquel

oclacitinib maleate

  • Email
  • Help

About

This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

What is Apoquel?

Apoquel is a veterinary medicine that contains the active substance oclaticinib. Apoquel tablets are available in three different strengths (3.5 mg, 5.4 mg and 16 mg) to cover a range of dog weights.

What is Apoquel used for?

Apoquel is used in dogs to treat pruritus (itching) associated with allergic dermatitis (inflammation of the skin). It is also used in dogs to treat atopic dermatitis. Treatment should be started at a dose of 0.4 – 0.6 mg per kilogram bodyweight twice a day for up to two weeks. Treatment may then be continued at the same dose given once a day. For the appropriate strength of tablets and number of tablets to be given, see the dosage table in the package leaflet.

How does Apoquel work?

The active substance in Apoquel, oclacitinib, is an immunomodulator (a medicine that changes the activity of the immune system) that works by blocking the action of enzymes known as Janus kinases. These enzymes play an important role in the processes of inflammation and itchiness including those involved in allergic dermatitis and atopic dermatitis in dogs. By blocking the enzymes, Apoquel reduces the inflammation and itchiness associated with the disease.

How has Apoquel been studied?

The action of Apoquel in pruritus associated with allergic dermatitis was studied in two field studies. In one, Apoquel was compared with prednisolone (an immunosuppressant) in 220 dogs, and in the other Apoquel was compared with placebo (dummy treatment) in 436 dogs. The measure of effectiveness in the studies was based on the assessment by the dog owner of the severity of the pruritus and improvements in the dog’s behaviour using a standard scale.

The atopic dermatitis indication was also investigated in two field studies. In both, Apoquel was compared with placebo. One study involved 220 dogs and the second involved 299 dogs. Studies in atopic dermatitis also used assessment of skin lesions on a score known as the canine atopic dermatitis extent and severity index (CADESI).

What benefit has Apoquel shown during the studies?

In the pruritus study comparing Apoquel with prednisolone, both medicines were shown to be effective, with a successful response seen in 68% of dogs treated with Apoquel, and 76% of those treated with prednisolone. When compared with placebo, the success rate was 67% for Apoquel-treated dogs and 29% for placebo-treated dogs.

For atopic dermatitis the treatment success rate for Apoquel-treated dogs in the first study was 66% compared with 4% in placebo-treated dogs using pruritus assessment; the results for CADESI scores were 49% and 4% respectively. The success rates in the second study were similar.

What is the risk associated with Apoquel?

The most common side effects were diarrhoea, vomiting and loss of appetite in decreasing order of frequency.

Apoquel should not be given to dogs less than one year of age or weighing less than 3 kg.

Apoquel should not be given to dogs with signs of immune suppression or progressive cancer as Apoquel has not been studied in such cases.

For a full list of all side-effects reported with Apoquel, see the package leaflet.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

Hands should be washed after handling the tablets.

In case of accidental ingestion, medical advice should be sought immediately and the package leaflet or the label shown to the doctor.

Why has Apoquel been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Apoquel exceed the risks for the approved indications and recommended that Apoquel be given a marketing authorisation. The benefit/risk balance may be found in the scientific discussion module of this EPAR.

Other information about Apoquel

The European Commission granted a marketing authorisation valid throughout the European Union, for Apoquel on 12/09/2013. Information on the prescription status of this product may be found on the label/outer package.

Name Language First published Last updated
Apoquel : EPAR - Summary for the public BG = bălgarski 15/10/2013  
Apoquel : EPAR - Summary for the public ES = español 15/10/2013  
Apoquel : EPAR - Summary for the public CS = čeština 15/10/2013  
Apoquel : EPAR - Summary for the public DA = dansk 15/10/2013  
Apoquel : EPAR - Summary for the public DE = Deutsch 15/10/2013  
Apoquel : EPAR - Summary for the public ET = eesti keel 15/10/2013  
Apoquel : EPAR - Summary for the public EL = elliniká 15/10/2013  
Apoquel : EPAR - Summary for the public EN = English 15/10/2013  
Apoquel : EPAR - Summary for the public FR = français 15/10/2013  
Apoquel : EPAR - Summary for the public IT = italiano 15/10/2013  
Apoquel : EPAR - Summary for the public LV = latviešu valoda 15/10/2013  
Apoquel : EPAR - Summary for the public LT = lietuvių kalba 15/10/2013  
Apoquel : EPAR - Summary for the public HU = magyar 15/10/2013  
Apoquel : EPAR - Summary for the public MT = Malti 15/10/2013  
Apoquel : EPAR - Summary for the public NL = Nederlands 15/10/2013  
Apoquel : EPAR - Summary for the public PL = polski 15/10/2013  
Apoquel : EPAR - Summary for the public PT = português 15/10/2013  
Apoquel : EPAR - Summary for the public RO = română 15/10/2013  
Apoquel : EPAR - Summary for the public SK = slovenčina 15/10/2013  
Apoquel : EPAR - Summary for the public SL = slovenščina 15/10/2013  
Apoquel : EPAR - Summary for the public FI = suomi 15/10/2013  
Apoquel : EPAR - Summary for the public SV = svenska 15/10/2013  
Apoquel : EPAR - Summary for the public HR = Hrvatski 15/10/2013  

This EPAR was last updated on 08/01/2014 .

Authorisation details

Product details

Product details for Apoquel
NameApoquel
Agency product numberEMEA/V/C/002688
Active substance

oclacitinib maleate

International non-proprietary name (INN) or common name

oclacitinib maleate

Species Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codeQD11AH90

Publication details

Publication details for Apoquel
Marketing-authorisation holder

Zoetis Belgium SA

Revision1
Date of issue of marketing authorisation valid throughout the European Union12/09/2013

Contact address:

Zoetis Belgium SA
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

Product information

25/10/2013  Apoquel -EMEA/V/C/002688 -IA/0001

Name Language First published Last updated
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - Product Information HR = Hrvatski 15/10/2013 08/01/2014

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014
Apoquel : EPAR - All Authorised presentations HR = Hrvatski 15/10/2013 08/01/2014

Pharmacotherapeutic group

Agents for dermatitis, excluding corticosteroids

Therapeutic indication

Treatment of clinical manifestations of Pruritus associated with Allergic Dermatitis in dogs.

Treatment of clinical manifestations of Atopic Dermatitis in dogs.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Apoquel : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 08/01/2014  

Initial marketing-authorisation documents

Name Language First published Last updated
Apoquel : EPAR - Public assessment report HR = Hrvatski 15/10/2013  
CVMP summary of positive opinion for Apoquel HR = Hrvatski 19/07/2013